Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
BACKGROUND: G12C is a mutation that occurs in approximately 3 to 4% of patients with metastatic colorectal cancer. Monotherapy with KRAS G12C inhibitors has yielded only modest efficacy. Combining the KRAS G12C inhibitor sotorasib with panitumumab, an epidermal growth factor receptor (EGFR) inhibitor, may be an effective strategy. METHODS: G12C who had not received previous treatment with a KRAS G12C inhibitor to receive sotorasib at a dose of 960 mg once daily plus panitumumab (53 patients), sotorasib at a dose of 240 mg once daily plus panitumumab (53 patients), or the investigator's choice of trifluridine-tipiracil or regorafenib (standard care; 54 patients). The primary end point was progression-free survival as assessed by blinded independent central review according to the Response Evaluation Criteria in Solid Tumors, version 1.1. Key secondary end points were overall survival and objective response. RESULTS: After a median follow-up of 7.8 months (range, 0.1 to 13.9), the median progression-free survival was 5.6 months (95% confidence interval [CI], 4.2 to 6.3) and 3.9 months (95% CI, 3.7 to 5.8) in the 960-mg sotorasib-panitumumab and 240-mg sotorasib-panitumumab groups, respectively, as compared with 2.2 months (95% CI, 1.9 to 3.9) in the standard-care group. The hazard ratio for disease progression or death in the 960-mg sotorasib-panitumumab group as compared with the standard-care group was 0.49 (95% CI, 0.30 to 0.80; P = 0.006), and the hazard ratio in the 240-mg sotorasib-panitumumab group was 0.58 (95% CI, 0.36 to 0.93; P = 0.03). Overall survival data are maturing. The objective response was 26.4% (95% CI, 15.3 to 40.3), 5.7% (95% CI, 1.2 to 15.7), and 0% (95% CI, 0.0 to 6.6) in the 960-mg sotorasib-panitumumab, 240-mg sotorasib-panitumumab, and standard-care groups, respectively. Treatment-related adverse events of grade 3 or higher occurred in 35.8%, 30.2%, and 43.1% of patients, respectively. Skin-related toxic effects and hypomagnesemia were the most common adverse events observed with sotorasib-panitumumab. CONCLUSIONS: In this phase 3 trial of a KRAS G12C inhibitor plus an EGFR inhibitor in patients with chemorefractory metastatic colorectal cancer, both doses of sotorasib in combination with panitumumab resulted in longer progression-free survival than standard treatment. Toxic effects were as expected for either agent alone and resulted in few discontinuations of treatment. (Funded by Amgen; CodeBreaK 300 ClinicalTrials.gov number, NCT05198934.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interestingly, KRAS G12C (glycine to cysteine) can be targeted using the covalent inhibitors, such as sotorasib, in combination with EGFR antagonists, such as panitumumab [75].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [75]
In the citing paper
“While KRAS and EGFR dual targeting holds promise in KRAS-mutant CRC, responses are often short-lived; most patients relapse within months due to acquired resistance.”
From Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer (2026) · cites this paper as [6]
In the citing paper
“While dual KRAS and epidermal growth factor receptor (EGFR) inhibition shows promise in treating KRAS-mutant colorectal cancer (CRC), resistance remains a major challenge.”
From Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer (2026) · cites this paper as [6]
In the citing paper
“the phase 3 CodeBreaK 300 trial comparing sotorasib at two doses (960 mg or 240 mg) plus panitumumab with investigator's choice of trifluridine/tipiracil or regorafenib in patients with chemotherapy-refractory KRAS G12C-mutated metastatic colorectal cancer was ongoing, and has shown improved progression-free survival with this combination strategy at both the doses tested. 19”
From Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial (2024) · cites this paper as [19]
In the citing paper
“Clinical studies of other KRAS G12C inhibitors, such as sotorasib and adagrasib, support this hypothesis, with higher response rates observed when used in combination with an EGFR inhibitor compared to when used as single-agent treatment in patients with CRC16–20.”
From Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial (2024) · cites this paper as [17]
23 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
Self-citationSotorasib for Lung Cancers with KRAS p.G12C Mutation
Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103695 · Cited by 1,849
Self-citationRandomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Mayer, R. J., Van Cutsem, E., Falcone, A., Yoshino, T., Garcia-Carbonero, R., Mizunuma, N., Yamazaki, K., Shimada, Y., Tabernero, J., Komatsu, Y., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414325 · Cited by 1,431
Acquired Resistance to KRAS G12C Inhibition in Cancer
Awad, M. M., Liu, S., Rybkin, I. I., Arbour, K. C., Dilly, J., Zhu, V. W., Johnson, M. L., Heist, R. S., Patil, T., Riely, G. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105281 · Cited by 1,247
Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation
Jänne, P. A., Riely, G. J., Gadgeel, S. M., Heist, R. S., Ou, S.-H. I., Pacheco, J. M., Johnson, M. L., Sabari, J. K., Leventakos, K., Yau, E., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2204619 · Cited by 1,061
Tabernero, J., Grothey, A., Van Cutsem, E., Yaeger, R., Wasan, H., Yoshino, T., Desai, J., Ciardiello, F., Loupakis, F., Hong, Y. S., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02088 · Cited by 569
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C
Yaeger, R., Weiss, J., Pelster, M. S., Spira, A. I., Barve, M., Ou, S.-H. I., Leal, T. A., Bekaii-Saab, T. S., Paweletz, C. P., Heavey, G. A., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212419 · Cited by 527
Cited by
Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
Passaro, A., Al Bakir, M., Hamilton, E. G., Diehn, M., André, F., Roy-Chowdhuri, S., Mountzios, G., Wistuba, I. I., Swanton, C., & Peters, S. (2024) · Cell · doi:10.1016/j.cell.2024.02.041 · Cited by 672
“As example, drugs targeting specifically KRAS G12C mutations 7 and 542/545/1047 PIK3CA hotspot mutations 8 have been developed.”
Targeting cytokine and chemokine signaling pathways for cancer therapy
Yi, M., Li, T., Niu, M., Zhang, H., Wu, Y., Wu, K., & Dai, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01868-3 · Cited by 455
Eng, C., Yoshino, T., Ruíz-García, E., Mostafa, N., Cann, C. G., O'Brian, B., Benny, A., Perez, R. O., & Cremolini, C. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00360-x · Cited by 449
Self-citationMosele, M. F., Westphalen, C. B., Stenzinger, A., Barlesi, F., Bayle, A., Bièche, I., Bonastre, J., Castro, E., Dienstmann, R., Krämer, A., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.04.005 · Cited by 415
Singhal, A., Li, B. T., & O’Reilly, E. M. (2024) · Nature Medicine · doi:10.1038/s41591-024-02903-0 · Cited by 332
“…improved clinical outcomes in CRC, with a combination of sotorasib and panitumumab (anti-EGFR) demonstrating an ORR of 26.4% and a median PFS of 5.6 months as compared with standard of care (trifluridine/tipiracil or regorafenib; ORR of 0%, PFS of 2.2 months) in the phase 3 CodeBreaK 300 trial 38 .”
InfluentialKRAS inhibitors: resistance drivers and combinatorial strategies
Isermann, T., Sers, C., Der, C. J., & Papke, B. (2025) · Trends in Cancer · doi:10.1016/j.trecan.2024.11.009 · Cited by 196
Exploiting the therapeutic implications of KRAS inhibition on tumor immunity
Molina-Arcas, M., & Downward, J. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.02.012 · Cited by 152
Yaeger, R., Uboha, N. V., Pelster, M. S., Bekaii-Saab, T. S., Barve, M., Saltzman, J., Sabari, J. K., Peguero, J. A., Paulson, A. S., Jänne, P. A., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0217 · Cited by 139
“22).”
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial
Desai, J., Alonso, G., Kim, S. H., Cervantes, A., Karasic, T., Medina, L., Shacham-Shmueli, E., Cosman, R., Falcon, A., Gort, E., et al. (2024) · Nature Medicine · doi:10.1038/s41591-023-02696-8 · Cited by 144
“%) and adagrasib plus cetuximab (46%), as well as single-agent treatment of patients with CRC (35.9% for divarasib, 9.7% for sotorasib and 19% for adagrasib) 16,17,20 .”
BackgroundInfluentialSelf-citationUpdate on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer
Underwood, P. W., Ruff, S. M., & Pawlik, T. M. (2024) · Cells · doi:10.3390/cells13030245 · Cited by 130
“A recent phase 3, multicenter, randomized trial compared sotorasib plus panitumumab to standard care in patients with mCRC refractory to standard therapy [41].”
BackgroundKuboki, Y., Fakih, M., Strickler, J., Yaeger, R., Masuishi, T., Kim, E. J., Bestvina, C. M., Kopetz, S., Falchook, G. S., Langer, C., et al. (2024) · Nature Medicine · doi:10.1038/s41591-023-02717-6 · Cited by 103
“…plus panitumumab with the investigator’s choice of trifluridine–tipiracil or regorafenib in patients with chemotherapy-refractory KRAS G12C -mutated metastatic colorectal cancer was ongoing and has shown improved progression-free survival with this combination strategy at both the doses tested 19 .”
InfluentialSelf-citationCombinatorial strategies to target RAS-driven cancers
Perurena, N., Situ, L., & Cichowski, K. M. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00679-6 · Cited by 114
Consensus, debate, and prospective on pancreatic cancer treatments
Wang, J., Yang, J., Narang, A. K., He, J., Wolfgang, C. L., Li, K., & Zheng, L. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01613-x · Cited by 109
Targeting the EGFR signalling pathway in metastatic colorectal cancer
Napolitano, S., Martini, G., Ciardiello, D., Tufo, S. D., Martinelli, E., Troiani, T., & Ciardiello, F. (2024) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(23)00479-x · Cited by 108
KRAS G12C inhibitor combination therapies: current evidence and challenge
Miyashita, H., Kato, S., & Hong, D. S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1380584 · Cited by 85
“Panitumumab is a fully human monoclonal antibody that inhibits EGFR, which was combined with sotorasib for chemotherapy-refractory metastatic colorectal cancer with KRAS G12C mutation in CodeBreaK 300, a phase 3, multicenter, open-label, randomized trial (29).”
Molecular principles underlying aggressive cancers
Nussinov, R., Yavuz, B. R., & Jang, H. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02129-7 · Cited by 97
Wang, F., Chen, G., Zhang, Z., Yuan, Y., Wang, Y., Gao, Y., Sheng, W., Wang, Z., Li, X., Yuan, X., et al. (2024) · 癌症:英文版 · doi:10.1002/cac2.12639 · Cited by 106
“…that in KRAS G12C mutant advanced colorectal cancer patients with standard treatment failure, the combination of KRAS G12C inhibitor Sotora-sib and panitumumab significantly prolonged PFS [135] compared with the investigator’s choice regimen (Trifluri-dine/Tipiracil [TAS-102] or Regorafenib).”
Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment
Gmeiner, W. H. (2024) · Cancers · doi:10.3390/cancers16051029 · Cited by 78
“Sotorasib and adagrasib both displayed increased activity in combination with panitumumab [83] (CODEBREAK 300, NCT05198934) and cetuximab [84] (KRYSTAL-1, NCT03785249), respectively.”
BackgroundCracking the EGFR code: Cancer biology, resistance mechanisms, and future therapeutic frontiers
Du, Y.-F., Karatekin, F., Wang, W. K., Hong, W., & Gandhi, T. K. B. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100076 · Cited by 114
MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer
Casacuberta‐Serra, S., González-Larreategui, Í., Capitán-Leo, D., & Soucek, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01907-z · Cited by 99
The next-generation KRAS inhibitors…What comes after sotorasib and adagrasib?
Oya, Y., Imaizumi, K., & Mitsudomi, T. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107886 · Cited by 65
Guo, H., Xu, X., Zhang, J., Du, Y., Yang, X., He, Z., Zhao, L., Liang, T., & Guo, L. (2024) · Pharmaceuticals · doi:10.3390/ph17081048 · Cited by 83
“Recent milestones, exemplified by the Food and Drug Administration (FDA) approval of Amgen’s Kirsten rat sarcoma viral oncogene-G12C (KRAS-G12C) inhibitor sotorasib [3–5], have provided valuable insights into cancer treatment.”
BackgroundNie, F., Sun, X., Sun, J., Zhang, J., & Wang, Y. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02593-8 · Cited by 99
Response and Resistance to RAS Inhibition in Cancer
Ebright, R. Y., Dilly, J., Shaw, A. T., & Aguirre, A. J. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-0349 · Cited by 83
A neomorphic protein interface catalyzes covalent inhibition of RAS G12D aspartic acid in tumors
Weller, C. E., Burnett, G. L., Jiang, L., Chakraborty, S., Zhang, D., Vita, N. A., Dilly, J., Kim, E., Maldonato, B. J., Seamon, K. J., et al. (2025) · Science · doi:10.1126/science.ads0239 · Cited by 78
Cremolini, C., Chalabi, M., Élez, E., Fassan, M., Gelli, M., Goèré, D., Modest, D. P., Viladot, C. M., Osterlund, P. J., Ricke, J., et al. (2026) · Annals of Oncology · doi:10.1016/j.annonc.2026.03.005 · Cited by 117
Self-citationKRAS: the Achilles’ heel of pancreas cancer biology
Drizyte‐Miller, K., Talabi, T., Somasundaram, A., Cox, A. D., & Der, C. J. (2025) · Journal of Clinical Investigation · doi:10.1172/jci191939 · Cited by 73
“Indeed, pancreatic cancer is projected to surpass CRC and become the second leading cause of cancer-related mortality by 2040 (2).”
InfluentialPietrantonio, F., Salvatore, L., Esaki, T., Modest, D. P., Lopez-Bravo, D. P., Taieb, J., Karamouzis, M. V., Ruiz-Garcia, E., Kim, T. W., Kuboki, Y., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-02026 · Cited by 51
Self-citationCurrent landscape of innovative drug development and regulatory support in China
Tan, R., Hua, H., Zhou, S., Yang, Z., Yang, C., Huang, G., Zeng, J., & Zhao, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02267-y · Cited by 51
Targeting KRAS G12C Mutation in Colorectal Cancer, A Review: New Arrows in the Quiver
Ros, J., Vaghi, C., Baraibar, I., Gonzalez, N. S., Rodríguez-Castells, M., García, A., Alcaráz, A., Salvà, F., Tabernero, J. M., & Élez, E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063304 · Cited by 62
“The combination of sotorasib and panitumumab has also been investigated [36,37].”
BackgroundResultCetuximab as a Key Partner in Personalized Targeted Therapy for Metastatic Colorectal Cancer
Gonzalez, N. S., Ros, J., Baraibar, I., Salvà, F., Rodríguez-Castells, M., Alcaráz, A., García, A., Tabernero, J. M., & Élez, E. (2024) · Cancers · doi:10.3390/cancers16020412 · Cited by 57
“Recently, the Phase III Codebreak 300 data have been published [62].”
BackgroundJohnson, D., Chee, C. E., Wong, W., Lam, R. C. T., Tan, I. B. H., & Ma, B. B. Y. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102700 · Cited by 52
State-of-the-Art Management of Colorectal Cancer: Treatment Advances and Innovation
Pathak, P., Chan, G. H. J., Deming, D. A., & Chee, C. E. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_438466 · Cited by 49
Current and emerging concepts for systemic treatment of metastatic colorectal cancer
Steup, C., Kennel, K. B., Neurath, M. F., Fichtner-Feigl, S., & Greten, F. R. (2025) · Gut · doi:10.1136/gutjnl-2025-335412 · Cited by 39
Zhang, J., Lim, S. M., Yu, M. R., Chen, C., Wang, J., Wang, W., Rui, H., Lu, J., Lü, S., Mok, T. S. K., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0006 · Cited by 42
“In line with these mechanisms, combining a KRAS G12C inhibitor with anti-EGFR antibodies has resulted in improved clinical benefits for multiple KRAS G12C inhibitors (39, 55, 56).”
BackgroundCiracì, P., Studiale, V., Taravella, A., Antoniotti, C., & Cremolini, C. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00965-0 · Cited by 53
“In this regard, the combination of sotorasib plus panitumumab might be the preferred choice based on data from a randomized trial 95 .”
InfluentialSelf-citationHamid, M. A., Pammer, L. M., Oberparleiter, S., Günther, M., Amann, A., Gruber, R., Mair, A., Nocera, F. I., Ormanns, S., Zimmer, K., et al. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00892-y · Cited by 49
“Such an investigation would provide crucial insights for patient strati fi cation, particularly in light of the advent of mutant selective KRAS inhibitors 67,68 .”
InfluentialMAPK-driven epithelial cell plasticity drives colorectal cancer therapeutic resistance
White, M., Mills, M. L., Millett, L. M., Gilroy, K. L., Hong, Y., Zeiger, L. B., Simpson, R. J., Corry, S. M., Ligeza, A., Lannagan, T. R. M., et al. (2025) · Nature · doi:10.1038/s41586-025-09916-w · Cited by 54
Puzzo, M., Santo, M. D., Morelli, C., Leggio, A., & Pasqua, L. (2024) · Small Science · doi:10.1002/smsc.202400113 · Cited by 42
Martín-Arana, J., Gimeno-Valiente, F., Henriksen, T. V., García-Micó, B., Martínez-Castedo, B., Gambardella, V., Martínez‐Ciarpaglini, C., Lucas, B. P.-D., Huerta, M., Camblor, D. G., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-00960-z · Cited by 45
Ahn, D. H., Ridinger, M., Cannon, T. L., Mendelsohn, L., Starr, J. S., Hubbard, J. M., Kasi, A., Barzi, A., Samuëlsz, E., Karki, A., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco-24-01266 · Cited by 44
Al-Karmalawy, A. A., Eissa, M. E., Ashour, N. A., Yousef, T. A., Khatib, A. O. A., & Hawas, S. S. (2025) · RSC Advances · doi:10.1039/d5ra05472a · Cited by 48
Puzzo, M., Santo, M. D., Morelli, C., Leggio, A., Catalano, S., & Pasqua, L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031313 · Cited by 35
Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in KRAS -mutant cancers
Jansen, R. A., Mainardi, S., Dias, M. H., Bosma, A. R., van Dijk, E., Selig, R., Albrecht, W., Laufer, S., Zender, L., & Bernards, R. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2319492121 · Cited by 26
“Indeed, adding the EGFR blocking antibody panitumumab to sotorasib appears to deliver some clinical benefit, indicating that combination therapies are required to improve responses to KRAS inhibition (17).”
BackgroundActivity and resistance to KRASG12C inhibitors in non-small cell lung cancer and colorectal cancer
Ye, W., Lu, X., Qiao, Y., & Ou, W. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189108 · Cited by 26
Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer
Zhang, Y., Chen, J., She, Y., Fang, Z., Zhang, Y., Ruan, D., Guo, W., Liao, J., Zhou, W., Lao, J., et al. (2026) · Cancer Cell · doi:10.1016/j.ccell.2025.10.010 · Cited by 23
Current and Emerging Treatment Paradigms in Colorectal Cancer: Integrating Hallmarks of Cancer
de Torres, C. S., Baraibar, I., Gonzalez, N. S., Ros, J., Salvà, F., Rodríguez-Castells, M., Alcaráz, A., García, A., Tabernero, J. M., & Élez, E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25136967 · Cited by 29
“[25].”
Tanaka, N., & Ebi, H. (2024) · Cancer Science · doi:10.1111/cas.16441 · Cited by 30
“Additionally, sotorasib combined with panitumumab has also shown effectiveness in this patient population [59].”
D3S-001 in advanced solid tumors with KRASG12C mutations: a phase 1 trial
Cho, B. C., Lü, S., Lee, M. A., Song, Z., Park, J., Lim, S. M., Li, Z., Zhao, J., Richardson, G. E., Zhang, Y., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03688-6 · Cited by 28
“Based on its high selectivity and the wide therapeutic index predicted during toxicology studies (predicted efficacious exposure 17-and 9-fold below the pharmacokinetic exposure at the highest dose that was not severely toxic based on C max and AUC, respectively, in a good laboratory practice study…”
Advances in structure-based allosteric drug design
Li, R., He, X., Wu, C., Li, M., & Zhang, J. (2024) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2024.102974 · Cited by 22
Ruan, D.-Y., Wu, H.-X., Xu, Y., Munster, P. N., Deng, Y., Richardson, G., Yan, D., Lee, M.-A., Lee, K.-W., Pan, H., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02274-z · Cited by 22
“16 Based on these fi ndings, FDA granted accelerated approval to adagrasib plus cetuximab on June 21, 2024, and approval to sotorasib plus panitumumab on January 16, 2025.”
Evolution of direct RAS inhibitors: from undruggable target to clinical breakthroughs
Wang, X., Wu, J., Xiao, A., Wang, J., & Tian, J. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02364-0 · Cited by 29
Hochmair, M. J., Vermaelen, K. Y., Mountzios, G., Carcereny, E., Dooms, C., Lee, S., Mórocz, É., Kato, T., Ciuleanu, T., Dy, G. K., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114204 · Cited by 21
Self-citationBiological and Clinical Characteristics of Proximal Colon Cancer: Far from Its Anatomical Subsite
Yang, Q. Z., Qu, R., Lu, S., Zhang, Y., Zhang, Z., & Fu, W. (2024) · International Journal of Medical Sciences · doi:10.7150/ijms.97574 · Cited by 21
“Additionally, another clinical trial demonstrated that increasing the dosage of the KRAS G12C inhibitor sotorasib within a safe range can improve patients' PFS[138].”
BackgroundStucchi, E., Bartolini, M., Airoldi, M., Fazio, R., Daprà, V., Mondello, G., Prete, M. G., Puccini, A., & Santoro, A. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2336069 · Cited by 20
“In addition, the CodeBreaK 300 open-label, phase III trial published in 2023 compared the efficacy of the KRASG12C inhibitor sotorasib plus panitumumab with the standard of care (SOC) in 160 patients with chemorefractory KRASG12C - mutant mCRC [73].”
BackgroundMethodInfluentialExploring Predictive and Prognostic Biomarkers in Colorectal Cancer: A Comprehensive Review
Ashouri, K., Wong, A., Mittal, P., Torres‐Gonzalez, L., Lo, J. H., Soni, S., Algaze, S. D., Khoukaz, T., Zhang, W., Yang, Y., et al. (2024) · Cancers · doi:10.3390/cancers16162796 · Cited by 24
“Early data demonstrate superior progression free survival (PFS) in both sotorasib groups relative to SOC (960 mg: 5.6 months vs. 240 mg: 3.9 months vs. SOC: 2.2 months) (NCT05198934) [23].”
BackgroundMethodInfluentialPietrantonio, F., Morano, F., Niger, M., Ghelardi, F., Chiodoni, C., Palazzo, M., Nichetti, F., Manca, P., Cristarella, E., Doldi, V., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-2611 · Cited by 23
“The prognosis of metastatic colorectal cancer (mCRC) remains unfavorable despite several recent advances (1), and there is urgent need for novel therapeutic strategies in the refractory setting (2, 3).”
Self-citationGenetic, Epidemiological, Clinical, and Therapeutic Trajectories in Colon and Rectal Cancers
Capuozzo, M., Picone, C., Sabbatino, F., Santorsola, M., Caraglia, F., Iervolino, D., Sirica, R., Gualillo, O., Mauro, G. D., Castiello, R., et al. (2025) · Cancers · doi:10.3390/cancers17213438 · Cited by 28
“These advances have generated a rapidly evolving therapeutic landscape in which precise RAS genotyping—including codon-and allele-level annotation—has become essential for patient selection and clinical trial design [8,9] 2.4.”
InfluentialAdvances in Personalized Oncology
Mechahougui, H., Gutmans, J., Colarusso, G., Gouasmi, R., & Friedlaender, A. (2024) · Cancers · doi:10.3390/cancers16162862 · Cited by 21
“Recently, in the phase III trial CodeBreaK 300 investigating KRAS G12C inhibitor plus an EGFR inhibitor in patients with chemorefractory metastatic colorectal cancer, both doses of sotorasib in combination with panitumumab resulted in longer progression-free survival than standard treatment [164].”
BackgroundTargeting RAF dimers in RAS mutant tumors: From biology to clinic
Yin, H., Tang, Q., Xia, H., & Bi, F. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.02.018 · Cited by 21
“A phase III clinical trial involving 160 patients with chemorefractory CRC reported that the combination of sotorasib and panitumumab (EGFRi) significantly extended progression-free survival (PFS) compared to the standard treatment regimen 194 .”
BackgroundCutshaw, G., Joshi, N., Wen, X., Quam, E., Bogatcheva, G., Hassan, N. A., Uthaman, S., Waite, J. R., Sarkar, S., Singh, B., et al. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202410919 · Cited by 23
Seligmann, J. F., Morton, D. G., Elliott, F., Handley, K., Gray, R. G., Seymour, M., Glimelius, B. L. G., Magill, L., Williams, C. J. M., Quirke, P., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2024.12.013 · Cited by 18
Yuan, Y., Deng, Y., Jin, Y., Guo, Z., Pan, Y., Wang, C., Wang, Z., Hu, Y., Hua, D., Meng, X., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02315-7 · Cited by 22
“31 These fi ndings highlight the ORR improvements with the combination of KRAS G12C inhibitor and anti-EGFR antibody in patients with KRAS G12C -mutated metastatic CRC.”
Targeting KRAS Oncogene for Patients With Colorectal Cancer: A New Step Toward Precision Medicine
Şahin, İ. H., Saridogan, T., Ayasun, R., Syed, M. P., Gorantla, V. C., Malhotra, M. K., Thomas, R. A., Rhee, J. C., Zhang, J. Y., Hsu, D. J., et al. (2024) · JCO Oncology Practice · doi:10.1200/op.23.00787 · Cited by 14
Lacroce, E., Nunziata, G., Cianniello, F., Limiti, E., Rainer, A., Vangosa, F. B., Sacchetti, A., Sponchioni, M., & Rossi, F. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.137659 · Cited by 19
Jacob, J., Anami, Y., High, P. C., Liang, Z., Subramanian, S., Ghosh, S. C., AghaAmiri, S., Guernsey-Biddle, C., Tran, H., Rowe, J. H., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-0798 · Cited by 22
Targeting the KRAS Oncogene for Patients with Metastatic Colorectal Cancer
Miao, R., Yu, J. B., & Kim, R. D. (2025) · Cancers · doi:10.3390/cancers17091512 · Cited by 20
“These and several other pan-RAS inhibitors are being investigated in KRAS-mutant mCRC (Table 2).”
Early-Onset Colorectal Cancer: From Genetic Discovery to Clinical Innovation
Turk, A. A., Mondaca, S., Nervi, B., Morris, A. D., Finer, Z. R., & Holowatyj, A. N. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-473618 · Cited by 20
Braicu, V., Stelian, P., Lazăr, F. O., Verdeş, G., Brebu, D. A., DuŢă, C. C., Fizedean, C. M., Ignuta, F., Dănilă, A.-I., & Cozma, G. V. (2024) · Diseases · doi:10.3390/diseases12040079 · Cited by 16
Combining EGFR and KRAS G12C Inhibitors for KRAS G12C Mutated Advanced Colorectal Cancer
Miyashita, H., & Hong, D. S. (2024) · Journal of Cancer Immunology · doi:10.33696/cancerimmunol.6.086 · Cited by 16
“The same regimen was investigated in a phase III trial (CodeBreaK 300) for 53 patients with chemotherapy-refractory KRAS G12C mutated advanced CRC without previous KRAS G12C inhibition [19].”
BackgroundTargeting the MAPK pathway for NRAS mutant melanoma: from mechanism to clinic
Wang, Y., Xu, G., & Xia, H. (2025) · British Journal of Dermatology · doi:10.1093/bjd/ljaf178 · Cited by 15
Caughey, B. A., & Strickler, J. H. (2023) · Drugs · doi:10.1007/s40265-023-01980-8 · Cited by 18
ErbB/HER family in cancer immunology: therapeutic advances and mechanisms
Yin, L., Zhang, H., Shang, Y., Wu, S., & Jin, T. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104436 · Cited by 14
Alagesan, B., Varghese, A. M., Ang, C., Gutiérrez, M., Kamar, M., Passhak, M., Geva, R., Yarom, N., Lahav, M., Ligresti, R., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-3189 · Cited by 21
Prognostic value of specific KRAS mutations in patients with colorectal peritoneal metastases
Tonello, M., Baratti, D., Sammartino, P., Giorgio, A. D., Robella, M., Sassaroli, C., Framarini, M., Valle, M., Macrì, A., Graziosi, L., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.102976 · Cited by 13
“7,9,25 Besides G12C mutation, differential treatment according to speci fi c KRAS mutations has been tested in several clinical trials.”
BackgroundThe Retrofit: Lessons From Sotorasib's Dosing Conundrum
Singh, H., Vellanki, P. J., & Pazdur, R. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00310 · Cited by 14
Modest, D. P., Fakih, M., Salvatore, L., Esaki, T., Páez, D., Taïeb, J., Karamouzis, M. V., Ruíz‐García, E., Kim, T. W., Kuboki, Y., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00352-3 · Cited by 16
Self-citationColorectal Cancer: Genetic Underpinning and Molecular Therapeutics for Precision Medicine
Dosunmu, G. T., & Shergill, A. P. (2024) · Genes · doi:10.3390/genes15050538 · Cited by 20
Miguel, C. A.-D., Jiménez-Castro, J., Sanchez-Vegas, A., Díaz-López, S., & Chaves-Conde, M. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104454 · Cited by 14
The shadow of cancer therapeutic resistance: Unveiling the role of S-palmitoylation
Yang, X., Xu, M., Deng, Z., & Xu, B. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101264 · Cited by 14
Treatment Options in Late-Line Colorectal Cancer: Lessons Learned from Recent Randomized Studies
Tarpgaard, L. S., Winther, S. B., & Pfeiffer, P. (2023) · Cancers · doi:10.3390/cancers16010126 · Cited by 12
“Patients were randomized to two different doses of sotorasib (960 mg or 240 mg) in combination with panitumumab versus standard of care (SOC) (FTD/TPI or regorafinib) as second-or later-line therapy [49].”
MethodDose optimization of sotorasib: Has the burden of proof for the labeled dose been met?
Popat, S., & Ratain, M. J. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.115044 · Cited by 11
Candia, L., Cervantes, A. M. R., & Martinelli, E. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.11.015 · Cited by 14
Jazieh, K., Tsai, J., Solomon, S. R., Zhu, M., Sinicrope, F. A., Pedersen, K. S., Fernández-Zapico, M. E., & Xie, H. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-2948 · Cited by 15
Recent advances in therapeutic targeting of the KRAS pathway in cancer
Hitchen, N., Williams, S., & Desai, J. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108889 · Cited by 15
Combination Therapy and Appropriate Dosing to Target KRAS in Colorectal Cancer
Yaeger, R. D. (2023) · New England Journal of Medicine · doi:10.1056/nejme2311611 · Cited by 12
KRAS, a New Target for Precision Medicine in Colorectal Cancer?
Boilève, A., Smolenschi, C., Lambert, A., Boige, V., Delaye, M., Camilleri, G. M., Tarabay, A., Valéry, M., Fuerea, A., Pudlarz, T., et al. (2024) · Cancers · doi:10.3390/cancers16203455 · Cited by 11
Murciano-Goroff, Y. R., Hollebecque, A., Heist, R. S., Cassier, P. A., Han, J.-Y., Kim, S. Y., Sabari, J. K., Tosi, D., Sacher, A., Burns, T. F., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-69943-7 · Cited by 13
Self-citationPrecision immune regulation in KRAS-mutated cancers: the final piece of the puzzle?
Fu, S., Ma, J., Cai, C., Tan, J., Deng, X., Shen, H., Zeng, S., Chen, Y., & Han, Y. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03444-1 · Cited by 14
Khelwatty, S. A., Puvanenthiran, S., Seddon, A. M., Bagwan, I., Essapen, S., & Modjtahedi, H. (2025) · Cancers · doi:10.3390/cancers17172810 · Cited by 15
“Follow-up data from the CodeBreaK 300 phase III trial compared sotorasib plus pani-tumumab against standard care in chemorefractory KRAS G12C-mutant CRC, with early findings supporting improved progression-free survival and safety [145].”
Resistance to KRAS inhibition in advanced non-small cell lung cancer
Sreter, K. B., Catarata, M. J., von Laffert, M., & Frille, A. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1357898 · Cited by 12
Assessment of KRASG12C inhibitors for colorectal cancer
Piazza, G. A., Chandrasekaran, P., Maxuitenko, Y. Y., & Budhwani, K. I. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1412435 · Cited by 11
“In line with this, CodeBreak 101 (NCT04185883) reported an overall survival of 30% in 40 metastatic CRC patients (Table 1) treated with Panitumumab and Sotorasib combination therapy (17).”
BackgroundJiang, Z.-Z., Ye, S.-Q., Wu, Y., Zhou, C., Cao, F., & Tan, N. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107252 · Cited by 14
Švec, J., Onhajzer, J., & Kořínek, V. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104544 · Cited by 10
Precision Medicine for Metastatic Colorectal Cancer: Where Do We Stand?
Underwood, P. W., & Pawlik, T. M. (2024) · Cancers · doi:10.3390/cancers16223870 · Cited by 15
“A recent trial published in the New England Journal of Medicine evaluated sotorasib in chemorefractory mCRC [42].”
Ikushima, H., Watanabe, K., Shinozaki‐Ushiku, A., Oda, K., & Kage, H. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103998 · Cited by 12
“26,27 Therefore, it is reasonable that positive SHAP values were associated with a BRAF mutation, HER2 expression 3 þ , and KRAS codon 12 and 13 mutations, whereas negative SHAP values were associated with a KRAS codon 146 mutation (Figure 3A).”
Sütcüoğlu, O., Yıldırım, H. Ç., Almuradova, E., Günenç, D., & Yalçın, Ş. (2025) · Medicina · doi:10.3390/medicina61071202 · Cited by 10
Vascular malformations: from genetics to therapeutics
Morin, G., Galasso, I., & Canaud, G. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-025-00344-x · Cited by 10
Colon cancer biology and treatment in the era of precision oncology: A primer for Radiologists
Platt, J. R., Pennycook, S., Muthoo, C., Westwood, A. C., Frood, R. T., Beggs, A. D., Scarsbrook, A. F., Seligmann, J. F., & Tolan, D. J. M. (2025) · European Journal of Radiology · doi:10.1016/j.ejrad.2025.112000 · Cited by 13
Targeting the MAP Kinase Pathway in Colorectal Cancer: A Journey in Personalized Medicine
Appleyard, J. W., Williams, C. J. M., Manca, P., Pietrantonio, F., & Seligmann, J. F. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-0107 · Cited by 11
Self-citation
Metadata
- Authors
- Fakih, M. G., Salvatore, L., Esaki, T., Modest, D. P., Lopez-Bravo, D. P., Taieb, J., Karamouzis, M. V., Ruiz-Garcia, E., Kim, T.-W., Kuboki, Y., Meriggi, F., Cunningham, D., Yeh, K.-H., Chan, E., Chao, J., Saportas, Y., Tran, Q., Cremolini, C., & Pietrantonio, F.
- Affiliations
- Università Cattolica del Sacro Cuore (IT)
- From Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte (M.G.F.), and Amgen, Thousand Oaks (E.C., J.C., Y.S., Q.T.) — both in California; Oncologia Medica, Università Cattolica del Sacro Cuore, and Oncologia Medica, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome (L.S.), the Oncology Department, Fondazione Poliambulanza Istituto Ospedaliero, Brescia (F.M.), the Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa (C.C.), and the Medical Oncology Department, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan (F.P.) — all in Italy; the Department of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka (T.E.), and the Experimental Therapeutics and GI Oncology Department, National Cancer Center Hospital East, Kashiwa (Y.K.) — both in Japan; the Medicine Department of Hemato...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-12-07
- Volume
- 389
- Issue
- 23
- Pages
- 2125-2139
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4387859726
- Semantic Scholar
- 775955729cc149c0cdcaed25ee8100657413b921
- Cited by
- 398
- References
- 37
- Citations by year
- 2026: 127 · 2025: 143 · 2024: 121 · 2023: 7
- FWCI
- 48.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Funders
- Amgen (NA)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- sotorasib, panitumumab, KRAS G12C mutation, metastatic colorectal cancer, EGFR inhibition, KRAS G12C inhibitors, combination therapy, progression-free survival, overall survival, objective response, trifluridine/tipiracil, regorafenib, dose comparison, refractory cancer, targeted therapy
- MeSH terms
- Antineoplastic Agents, Immunological, Panitumumab, Immune Checkpoint Inhibitors, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Humans, Mutation, Phenylurea Compounds, Piperazines, Pyridines, Pyrimidines, Pyrrolidines, Thymine, Trifluridine, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.